Amgen Reports MariTide Weight Loss Holds Up With Fewer Doses

At a J.P. Morgan Healthcare Conference on Monday, Amgen Inc.(NASDAQ:AMGN) CEO Robert Bradway shared findings from part 2 of the Phase 2 Study of MariTide, its investigational obesity treatment. • Amgen stock is showing positive momentum. What’s the outlook for AMGN shares? Key Findings The large majority of participants maintained the weight loss achieved in part 1 for an additional 52 weeks on a lower monthly dose or quarterly dose of MariTide. The second year of MariTide treatment was very well tolerated, including at quarterly doses, with a very low incidence of nausea and vomiting, and no new safety signals observed. Improvements in cardiometabolic parameters were sustained with MariTide at effective maintenance doses for a full second year. In June 2025, Amgen released full results from part one of its phase 2 study of MariTide. In the phase 2 trial, MariTide showed up to 20% average weight loss in people with obesity without Type 2 diabetes and up to 17% in those with the condition, significantly outperforming placebo. Amgen also said a 24-week study of monthly MariTide for Type 2 diabetes with or without obesity showed a clinically meaningful reduction in both HbA1c (blood sugar levels) and weight. Amgen said it currently has six Phase 3 MariTide studies underway across obesity and related conditions, including diabetes, heart disease, and sleep apnea. Analyst Take William Blair says it is not particularly surprised by the 52-week data update, given what was already seen from Q8W dosing. There remains a question on what dose would be needed for quarterly maintenance dosing, particularly given that the 420 mg dose level is not being studied in current Phase 3 studies. Analyst Matt Phipps sees a differentiated product profile for MariTide versus currently approved GLP-1 therapies or those in late-stage development, and therefore potential for meaningful market share and a multibillion-dollar peak sales opportunity. Analyst Phipps also sees revenue upside potential from key assets and success with late-stage pipeline assets, and thus maintains the Outperform rating. AMGN Price Action: Amegen stock is up 0.46% at $325.80 at publication on Wednesday. Photo: Melnikov Dmitriy via Shutterstock